Abstract
Cardiovascular disease (CVD) accounts for more than 4.3 million deaths in Europe representing 48% of all deaths (British Heart Foundation. European Cardiovascular Disease Statistics 2008) and is predicted to be the number one killer by 2020 in our ageing societies facing major societal and economic changes around the globe [1]. The clinical manifestations of CVD are diverse and comprise myocardial infarction, stroke, aortic aneurysms, renal artery stenosis and gangrene (Fig. 3.1). In Europe, the single most common cause of death is coronary artery disease (CAD; 21% of men and 21% of women) followed by stroke (11% of men and 17% of women) and the remaining manifestations of CVD (11% of men and 15% of women) (British Heart Foundation. European Cardiovascular Disease Statistics 2008). Despite major reductions in mortality obtained in the setting of acute myocardial infarction [2], morbidity due to CVD remains of eminent importance across the world as quantified with the Disability Adjusted Life Years (DALY) as an aggregate of years of life lost to due to premature death and years of healthy life lost to disability (British Heart Foundation. European Cardiovascular Disease Statistics 2008). Currently, 70% of clinical events cannot be prevented with available drug therapy including statins [3] and at least 10% of coronary events occur in apparently healthy individuals in the absence of major traditional risk factors [4].
Keywords
- Percutaneous Coronary Intervention
- Optical Coherence Tomography
- Abdominal Aortic Aneurysm
- Abdominal Aortic Aneurysm
- Peripheral Artery Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367(9524):1747–1757
ox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA 297(17):1892–1900
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278
Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB et al (2003) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290(7):891–897
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952
Enos WF, Holmes RH, Beyer J (1986) Landmark article, July 18, 1953: Coronary disease among United States soldiers killed in action in Korea. Preliminary report, by. Enos WF, Holmes RH, Beyer J. JAMA 256(20):2859–2862
Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M et al (1992) A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 85(1):391–405
Cecchi E, Giglioli C, Valente S, Lazzeri C, Gensini GF, Abbate R et al (2011) Role of hemodynamic shear stress in cardiovascular disease. Atherosclerosis 214(2):249–256
Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B et al (2005) A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437(7057):426–431
Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI (2000) The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97(16):9052–9057
Cheng C, van Haperen R, de Waard M, van Damme LC, Tempel D, Hanemaaijer L et al (2005) Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. Blood 106(12):3691–3698
Chappell DC, Varner SE, Nerem RM, Medford RM, Alexander RW (1998) Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res 82(5):532–539
Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ et al (2006) Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 113(23):2744–2753
Tabas I, Williams KJ, Boren J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116(16):1832–1844
Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–95
Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508–519
Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH (2005) T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proceedings of the National Academy of Sciences of the United States of America, 21 Jan 21 2005
Gotsman I, Sharpe AH, Lichtman AH (2008) T-cell costimulation and coinhibition in atherosclerosis. Circ Res 103(11):1220–1231
Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802–815
Ait-Oufella H, Taleb S, Mallat Z, Tedgui A (2009) Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol 31(1):23–33
Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K (2006) Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 203(5):1273–1282
Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M et al (2009) Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J Exp Med 206(1):233–248
Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373–376
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340(8828):1111–1115
Bedarida GV, Bushell E, Haefeli WE, Blaschke TF, Hoffman BB (1993) Responsiveness to bradykinin in veins of hypercholesterolemic humans. Circulation 88(6):2754–2761
Charakida M, Masi S, Luscher TF, Kastelein JJ, Deanfield JE (2010) Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 31(23):2854–2861
Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T et al (2004) Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 110(18):2918–2923
Halcox JP, Donald AE, Ellins E, Witte DR, Shipley MJ, Brunner EJ et al (2009) Endothelial function predicts progression of carotid intima-media thickness. Circulation 119(7):1005–1012
Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106(6):653–658
Pistoia F, Cipollone F, Ferri C, Sara M, Sudano I, Desideri GB (2010) Cyclooxygenase and atherosclerosis: a smoking area. Curr Pharm Des 16(23):2567–2571
Linder L, Kiowski W, Buhler FR, Luscher TF (1990) Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 81(6):1762–1767
Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ et al (2008) Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31(4):776–782
Sudano I, Virdis A, Taddei S, Spieker L, Corti R, Noll G et al (2007) Chronic treatment with long-acting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension. Hypertension 49(2):285–290
Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hurlimann D et al (2007) Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 25(4):785–791
Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697
Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M et al (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117(17):2262–2269
Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106(17):2184–2187
Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74(6):1399–1406
Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al (2007) Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, 2004, and Brussels, 2006. Cerebrovasc Dis 23(1):75–80
Bots ML, Baldassarre D, Simon A, de Groot E, O’Leary DH, Riley W et al (2007) Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J 28(4):398–406
Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4):459–467
Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH et al (1998) The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128(4):262–269
Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN (2002) ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106(16):2055–2060
Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH et al (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297(12):1344–1353
Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM (2000) Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 101(6):598–603
Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ et al (2001) American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 37(5):1478–1492
Ricciardi MJ, Meyers S, Choi K, Pang JL, Goodreau L, Davidson CJ (2003) Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. Am Heart J 146(3):507–512
von Birgelen C, Hartmann M, Mintz GS, van Houwelingen KG, Deppermann N, Schmermund A et al (2004) Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110(12):1579–1585
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292(18):2217–2225
Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9):1071–1080
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13):1556–1565
Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG (2002) Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106(17):2200–2206
Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS et al (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364(3):226–235
Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK et al (2010) Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 31(4):401–415
Templin C, Meyer M, Muller MF, Djonov V, Hlushchuk R, Dimova I et al (2010) Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 31(14):1792–1801
Sones FM Jr, Shirey EK (1962) Cine coronary arteriography. Mod Concepts Cardiovasc Dis 31:735–738
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M et al (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360(3):213–224
Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH et al (1996) Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the cholesterol lowering atherosclerosis study. Circulation 93(1):34–41
Waters D, Craven TE, Lesperance J (1993) Prognostic significance of progression of coronary atherosclerosis. Circulation 87(4):1067–1075
Gruntzig A (1976) Percutaneous recanalisation of chronic arterial occlusions (Dotter principle) with a new double lumen dilatation catheter (author’s transl). Rofo 124(1):80–86
Serruys PW, Kutryk MJ, Ong AT (2006) Coronary-artery stents. N Engl J Med 354(5):483–495
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000 May) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20(5):1262–1275
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516
Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972
Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC et al (2010) Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 122(10):949–957
Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28(13):1598–1660
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29(23):2909–2945
Steffel J, Luscher TF, Tanner FC (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113(5):722–731
Klingenberg R, Hansson GK (2009) Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 30(23):2838–2844
Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB et al (2010) Cellular actors, toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 31(12):1457–1469
Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE et al (2005) Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 111(11):1355–1361
Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML (2003) Acute myocardial infarction. Lancet 361(9360):847–858
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13–20
Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37(2):577–617
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE et al (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355(6):549–559
Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431):331–337
North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325(7):445–453
European Carotid Surgery Trialists’ Collaborative Group (1991) MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 337(8752):1235–1243
Ringleb PA, Allenberg J, Bruckmann H, Eckstein HH, Fraedrich G, Hartmann M et al (2006) 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368(9543):1239–1247
Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP et al (2006) Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355(16):1660–1671
Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ et al (2010) Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (international carotid stenting study): an interim analysis of a randomised controlled trial. Lancet 375(9719):985–997
Kakkos SK, Tsolakis IA, Nicolaides AN (2010) Stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 363(18):1767, Author reply 1768
Bonati LH, Ederle J, McCabe DJ, Dobson J, Featherstone RL, Gaines PA et al (2009) Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 8(10):908–917
Ederle J, Bonati LH, Dobson J, Featherstone RL, Gaines PA, Beard JD et al (2009) Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 8(10):898–907
Reiff T, Stingele R, Eckstein HH, Fraedrich G, Jansen O, Mudra H et al (2009) Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial. Int J Stroke 4(4):294–299
Staub D, Schinkel AF, Coll B, Coli S, van der Steen AF, Reed JD et al (2010) Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaques. JACC Cardiovasc Imaging 3(7):761–771
Wahl A, Tai T, Praz F, Schwerzmann M, Seiler C, Nedeltchev K et al (2009) Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. JACC Cardiovasc Interv 2(2):116–123
Bayard YL, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E et al (2010) PLAATO (percutaneous left atrial appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 6(2):220–226
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl 1):S1–S75
Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285(19):2481–2485
Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):23–33
Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al (2006) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients With peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47(6):1239–1312
Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG (1994) Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 90(4):1866–1874
Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB et al (2000) A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109(7):523–530
Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P (2002) Findings of the naftidrofuryl in quality of life (NIQOL) European study program. Int Angiol 21(1):20–27
de Mast Q, Beutler JJ (2009) The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 27(7):1333–1340
White CJ (2006) Catheter-based therapy for atherosclerotic renal artery stenosis. Circulation 113(11):1464–1473
Zierler RE, Bergelin RO, Isaacson JA, Strandness DE Jr (1994) Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. J Vasc Surg 19(2):250–257, Discussion 7–8
Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C et al (2009) Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361(20):1953–1962
George JC, White CJ (2010) Renal artery stenting: lessons from ASTRAL (angioplasty and stenting for renal artery lesions). JACC Cardiovasc Interv 3(7):786–787
Brown LC, Powell JT (1999) Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK small aneurysm trial participants. Ann Surg 230(3):289–296, Discussion 96–97
Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM et al (2005) Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 352(23):2398–2405
EVAR Trial Participants (2005) Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 365(9478):2179–2186
Choke E, Cockerill G, Wilson WR, Sayed S, Dawson J, Loftus I et al (2005) A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 30(3):227–244
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286(11):1317–1324
Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24(11):987–1003
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195–2207
Koenig W, Ridker PM (2010) Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk > =5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J 32:75–83
Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A et al (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 114(4):281–288
Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107(3):391–397
Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302(1):37–48
Danesh J, Erqou S, Walker M, Thompson SG, Tipping R, Ford C et al (2007) The emerging risk factors collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 22(12):839–869
Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V et al (2009) Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38(1):217–231
Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M et al (2010) Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 30(5):946–952
Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117(23):3002–3009
Camm AJ, Luscher TF, Serruys PW (2009) The ESC textbook of cardiovascular medicine, 2nd edn. Oxford University Press, Oxford, pp 99–236
Camm AJ, Luscher TF, Serruys PW (2009) The ESC textbook of cardiovascular medicine, 2nd edn. Oxford University Press, Oxford, pp 597–664, pp 919–953
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag/Wien
About this chapter
Cite this chapter
Klingenberg, R., Hasun, M., Corti, R., Lüscher, T.F. (2012). Clinical Manifestations of Atherosclerosis. In: Wick, G., Grundtman, C. (eds) Inflammation and Atherosclerosis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0338-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0338-8_3
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0337-1
Online ISBN: 978-3-7091-0338-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)